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ABSTRACT 
Osteoarthritis (OA) is accepted as a major public health problem. It is one of the major causes of impaired function that reduces quality of life 
(QOL) worldwide. OA is a very common disorder affecting the joint cartilage. As there is no cure for OA, treatments currently focus on 
management of symptoms. Pain relief, improved joint function, and joint stability are the main goals of therapy. The muscle weakness and 
muscle atrophy contribute to the disease process. So, rehabilitation and physiotherapy were often prescribed with the intention to alleviate 
pain and increase mobility. However, as exercise has to be performed on a regular basis in order to counteract muscle atrophy , continuous 
exercise programs is recommended in people with degenerative joint disease. Therapeutic exercise regimes either focus on muscle 
strengthening and stretching exercises or on aerobic activity which can be land or water based. This article presents on overview of the current 
knowledge on OA and focuses on biomechanics, etiology, diagnosis and treatment strategies, conservative treatment including the physical 
therapy management are discussed. This information should assist health care practioners who treat patients with this disorder.  
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Introduction  
Osteoarthritis (OA) is a common chronic condition resulting 
in pain, fatigue, functional limitations, increased healthcare 
utilization and high economic costs to society [1]. The 
burden of OA is projected to increase, due in part to obesity 
and population aging [2]. While the prevalence of OA 
increases with age [3], there is a growing recognition that OA 
affects people at younger ages. Recent US data demonstrated 
that half of people with symptomatic knee OA are diagnosed 
by age 55 [4].  
Quadriceps strength deficits have been reported in 20%–
70% of patients with knee OA. Any improvement in muscle 
strength or peak power of the lower extremities with 
decreased levels of particular pain may be important and is a 
strong predictor of functional ability [5]. As lower limb 
musculature is the natural brace for the knee joint, 
potentially important muscle dysfunction may arise from 
either quadriceps weakness or relative weakness of the 
hamstrings in comparison to the quadriceps, usually 
assessed as the hamstrings: quadriceps (H:Q) ratio. An H:Q 
ratio of greater than or equal to 0.6 is considered to be 
normal [6]. Thus, evaluation of muscle dysfunction in 
relation to the knee joint should examine both quadriceps 
strength as well as the balance of muscle strength [6].  
The etiology of OA is related to repetitive mechanical loads 
and aging. Recent studies have separated the etiological 
factors into three main sub-groups: sex, anatomy, and body 
mass. The clinical manifestations are joint pain, stiffness; 
decreased range of joint movement, muscle weakness of the 
quadriceps and alterations in proprioception [7]. Decreased 
strength in the muscle groups involving the joints is 
significant because it causes progressive loss of function. 
These symptoms significantly restrict the individual’s ability 
to get up from a chair, walk, or climb stairs [3]. Walking with 
a limp, poor alignment of the limb, and instabilities can also 
be observed in individuals with OA. During movements, 
crepitating can be heard because of arthritis of the irregular 
joint surfaces [2]. Clinical knee OA usually is managed in 
primary care [8] with analgesics and non-pharmacological 
options, such as exercise [6]. Exercise has been shown to 
improve function, strength, walking speed, and self-efficacy 
and to reduce pain and the risk of other chronic conditions 
[9, 10]. Also, prevent or retard progression of the disease 
using physical and occupational therapy and exercise 
programs [3]. Plain radiographs are commonly used to 
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classify OA subjects for the purposes of clinical studies and 
joint space narrowing is often used as a measure of disease 
progression. Although plain radiography is at present, the 
‘‘gold standard’’ for evaluation of OA progression, it is 
brimful with problems related to the accurate reproduction 
of measurements of joint space width, especially in subjects 
who have knee OA [11]. A self-reported physical disability or 
assessment questionnaire most commonly used to assess the 
outcome of exercises for OA. The most popular specific 
questionnaire for knee OA is the Western Ontario and 
McMaster Universities OA index questionnaire (WOMAC) 
which reports pain, stiffness and daily function difficulties 
experienced by OA subjects [12].  
Several muscle groups support the knee. The two main 
muscle groups that control knee movement and stability are 
the quadriceps and the hamstrings. The quadriceps and 
hamstrings muscles have the potential to provide dynamic 
frontal-plane knee stability because of their abduction 
and/or adduction moment arms [13]. Using a neuromuscular 
biomechanical model, the quadriceps and hamstrings not 
only have the potential to support frontal-plane moments 
but also actually do provide support to abduction-adduction 
moments [14]. In the frontal plane, balanced co contraction 
of the quadriceps and hamstrings leads to increased joint 
compression, which should assist in knee joint stabilization 
[15]. The diminished co activation between the quadriceps 
and hamstrings in women may contribute to greater knee 
joint instability in women than in men. The strength 
relationship between the quadriceps femories and hamstring 
muscle have been measured and reported by various 
researchers [16, 17]. 
Classification 
1) Primary osteoarthritis (idiopathic)- 
 Localized 
o Hands – nodal osteoarthritis more than three joint 
sinvolved 
o Hip – eccentric, concentric, diffuse 
o Knee – medial tibiofemoral, lateral tibiofemoral, 
pattelofemoral 
o Spine – apophyseal, intervertebral, spondylosis 
 Generalized 
 Small (peripheral) joints 
 Large (central) joints 
 Mixed and spine 
 Erosive osteoarthritis 
2) Secondary- 
 Congenital and developmental disorders, bone 
dysplasias. 
 Post-surgery / injury – meniscectomy. 
 Endocrine – diabetes mellitus, acromegaly, 
hypothyroidism, hyperthyroidism, 
hyperparathyroidism, Cushing syndrome. 
 Metabolic – hemachromatosis, ochronosis, Marfan 
syndrome, Ehler-Danlos syndrome, Paget disease, gout, 
pseudo gout, Wilson’s disease, Hurler disease, Gaucher 
disease. 
 Rheumatologic– rheumatoid arthritis. 
 Neurological– Charcot joints. 
 Hematological – hemoglobinopathies. 
 Iatrogenic – intra-articular steroids.[18]  
Knee osteoarthritis 
The knee is the largest synovial joint in humans, it is 
composed by osseous structures(distal femur, proximal tibia, 
and patella), cartilage (meniscus and hyaline 
cartilage),ligaments and a synovial membrane. The latter is 
in charge of the production of the synovial fluid, which 
provides lubrication and nutrients to the avascular cartilage. 
Unfortunately, given the high use and stress of this joint, itis 
a frequent site for painful conditions including OA[19,20]OA 
is classified into two groups according to its etiology: 
primary (idiopathic or non-traumatic) and 
secondary(usually due to trauma or mechanical 
misalignment). Theseverity of the disease can also be graded 
according to theradiographical findings by the Kellgren–
Lawrence (KL)system described in 1957[21].It was believed 
that OA was exclusively a degenerative disease of the 
cartilage, however, latest evidence has proven that OA is a 
multifactorial entity, involving multiple causative factors like 
trauma, mechanical forces, inflammation, biochemical 
reactions, and metabolic derangements[22]. It is also known 
that the cartilaginous tissue is not the only one involved. 
Given its lack of vasculature and innervation, the cartilage, by 
itself is not capable of producing inflammation or pain at 
least on early stages of the disease. Hence, the source of pain 
is mainly derived from changes tothe non-cartilaginous 
components of the joint, like the joint capsule, synovium, 
subchondral bone, ligaments, and periarticular muscles. As 
the disease advances, these structure sare affected and 
changes including bone remodeling, osteophyte formation, 
weakening of periarticular muscles, laxity of ligaments, and 
synovial effusion can become evident[23].The role of 
inflammation is not well-understood and there is an ongoing 
debate to determine if the inflammatory reaction triggers the 
OA changes, or instead, the inflammation is secondary to the 
OA changes. Different from inflammatory arthritis, 
inflammation in OA is chronic and low-grade inflammation, 
involving mainly innate immune mechanisms. Synovitis 
(infiltration of inflammatory cells into the synovium) is a 
common finding of OA and it can be present in early stages of 
the disease but is more prevalent towards the more 
advanced stages and can be related withseverity.1 In OA, the 
synovial fluid has been found to contain multiple 
inflammatory mediators including plasma proteins(C-
reactive protein, proposed as a marker for development and 
progression of OA), prostaglandins (PGE2), 
 IL15, IL17, 
oxide, and complement components[24].Locally, all of these 
components can induce matrix metallo proteinases and other 
hydrolytic enzymes (including cyclooxygenase two and 
prostaglandin E)resulting in cartilage breakdown secondary 
to proteoglycan and collagen destruction[25].White blood 
cells are also involved, extracellular matrix breakdown 
releases certain molecules (damage-associated molecular 
patterns) that are recognized by the innate immune cells 
(macrophages and mast cells), usually as a protective 
mechanism. However, this prolonged and dysregulated 
degree of inflammation can lead to tissue destruction. In 
animal studies, macrophages have been found to be 
involvedin the development of osteophytes that are a 
pathological feature of OA. The body also has protective 
molecular mechanisms including various growth factors 
(insulin-like, platelet derived, fibroblast, and transforming 
growth factor B) which, unfortunately, are altered in patients 
with knee OA and may become harmful to the joint[19,25]. 
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Epidemiology  
Osteoarthritis (OA) of the knee is the most common form of 
joint disease and prevalence of both radio graphically 
evident and symptomatic. The females having higher 
prevalence than males (11.4% vs 6.8%) [26]. The gender 
difference in prevalence has recently been emphasized in a 
meta-analyses, which provides evidence for a greater risk in 
females for prevalent and incident knee OA [27]. The meta-
analysis also reported that females tend to have more severe 
knee OA radio graphically assessed than males and that the 
gender differences increase with age > 55 years. The 
prevalence of OA will increase as the population of the 
kingdom ages, especially if the incidence of obesity remains 
at over 50% in the 45+ age group [28].  
Etiology & Pathogenesis  
Modern imaging approaches recognize that OA is a whole 
joint disease which may involve multiple tissues which 
confer different phenotypes; subchondral bone in particular 
is integral to the pathogenesis and progression of OA. In 
particular, the area of subchondral bone at the femorotibial 
articulation is larger in OA knees than healthy controls and 
correlates with knee joint space narrowing, osteophytes [29].  
Pathogenetically, knee OA is characterized by structural 
changes in and around the knee joint. The predominant 
structural changes are the loss of cartilage and the formation 
of osteophytes. These changes are easily demonstrated radio 
graphically, and objective measures of disease severity are 
based on the amount of joint space loss (a reflection of 
cartilage loss) and the presence of osteophytes [30]. 
Furthermore, the subchondral bone scleroses in the early 
phases of OA and this process, possibly involving micro 
fractures has been suggested to be pathogenetic factors in 
the process of cartilage degeneration . In addition to these 
structural “hard tissue” changes, a number of changes in 
articular and periarticular soft-tissue occur with knee OA. 
These include synovial hyperplasia and joint effusions. 
Although knee OA is not classified as an inflammatory 
disease, a common sign of knee OA is synovial inflammation, 
detected using Ultrasonographic. In addition magnetic 
resonance imaging as well as orthoscopical inspection of the 
knee joint has also provided insights to the presence of 
inflammation in knee OA [31,32]. 
Structural changes: Mainly are reductions instainable 
proteoglycan, fibrillation, collagen crumping, chondrocyte 
multiplication or migration and loss of cartilage. Initially, 
localized areas of softening present apebbled texture at 
surface followed by disruption alongcollagen fiber planes 
(tangential flaking, vertical fibrillation). As deep clefts are 
formed in cartilage, nearby matrix gets depleted of 
metachromatic material indicating loss of proteoglycans. 
Subsequent focalproliferation of chondrocytes occurs as an 
attempt atlocal self-repair leading to irregularly shaped 
hyaline and fibro cartilage. Later new bone formation occurs 
in subchondral bone and at joint margins (osteophytes). 
Subarticular cysts predominate wherever overlying cartilage 
is thin or absent. Separated fragments of cartilage and bone 
may form loose bodies, undergo dissolution or become 
incorporated into synovium and proliferate locally. 
Synovium becomes thick and hypertrophied and capsule 
contracts with infiltration of lymphoid follicles, lymphocytes 
and macrophages. Calcification may occur as calcium crystals 
deposit in cartilage with presumed secondary uptake in 
synovium. Despite loss of bone and cartilage in some parts of 
joint, net effect of new cartilage and bone formation is an 
increase in joint size and remodelling of shape.[33,34]. 
Metabolic and biochemical changes in 
osteoarthritis cartilage 
• Generalized – Increased hydration and swelling with loss of 
tensile strength is noticed in early OA, whereas increase in 
type I collagen synthesis and progressive fall occurs in 
proteoglycan concentration in later stage of OA. 
• Specific collagens – Initial swelling of collagen fibrillar 
network with loss of type II collagen, specific cleavage of 
collagens and loss of tensile strength with increased content 
of collagen type IV. Type III and X collagen are also 
synthesized. 
• Proteoglycans – Increased extractability and decrease in 
monomer size because of specific cleavages by aggrecanases 
and metalloproteinases. 
• Cytokines, proteinases and inhibitors – There is increase in 
pro-inflammatory cytokines, aggrecanases, MMPs (matrix 
metalloproteinase), cathepsins and decrease in overall 
inhibitors (TIMP etc.)[35]. 
 Of the three major MMPs that degradenative collagen, MMPs 
-13 is most important, as it preferentially degrades type II 
collagen whose expression is greatly increased in OA. The 
aggrecanases belong to a family of extracellular proteases 
known as disintegrin and metalloproteases with thrombo 
spondinmotifs (ADAMTS). ADAMTS-4 and ADAMTS-5 
appearto be major enzymes in cartilage degeneration in 
arthritis. Whereas, IL-1beta synthesized by mononuclear 
cells(including synovial cells) in inflamed joint is 
consideredby many investigators as a prime mediator in 
cartilagematrix degradation and stimulates synthesis and 
secretion of many degradative enzymes in cartilage including 
latent collagenase, stronelysin, gelatinase and tissue 
plasminogen activator. The balance of active and latent 
enzymes is controlled to some extent by at least two enzyme 
inhibitors: TIMP and plasminogen activator inhibitor-1(PAT-
1).Which in turn are reglated by TGF-beta. However, the 
imbalance between proteoglycan synthesis and degradation 
isimportant in pathogenesis of cartilage breakdown. 
Growth Factors and Cytokines Anabolic 
 TGF (tissue growth factor beta- 1, 2 & 3) help in 
chondrocyte proliferation, matrix synthesis, modulate 
effects of IL-1 and increases proteinase inhibitors. 
 Fibroblast and platelet derived growth factors also help 
in differentiation and proliferation of chondrocytes and 
MMP production. 
 Insulin growth factor-1(IGF-1) increases 
glycosaminoglycan (GAG) and collagen synthesis. 
 Bone morphogenetic proteins increase matrix 
Synthesis[36]. 
Catabolic 
 Interleukin-I (IL-1) and tumor necrosis factor (TNFa) 
increase MMPs, inhibit GAG synthesis and can  further 
potentiate the degenerative cascade. 
 Oncostatin-M combines with IL-1 and TNF to promote 
matrix breakdown. 
 Others like IL-17 and IL-18 increase expression of IL-
1bð and IL-6 and increase MMP. 
 NO (nitric oxide) is a major catabolic factor produced 
by chondrocytes in response to proinflammatory 
cytokines such as IL-I beta and TNF-alpha. NO can 
inhibit collagen and proteoglycan synthesis, can 
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activate MMPs and cause an oxidative injury as well as 
produce apoptosis leading to degradation of articular 
cartilage. 
 Prostaglandins effects on chondrocytes metabolism are 
complex and include enhanced type II collagen 
synthesis, activation of MMPs, and promotion of 
apoptosis. In cartilage explants, IL-1beta induces COX-2 
expression and PGE2 production coordinate with 
proteoglycan degradation. Moreover, COX-2 inhibition 
prevents IL-1beta induced proteoglycan degradation 
[37,38]. 
Treatment 
OA is a progressive and degenerative condition, with unlikely 
regression and restoration of damaged structures. Thus, 
current management modalities are targeted towards 
symptom control unless the degree of severity dictates the 
necessity of surgical intervention with joint replacement. 
Currently, different guidelines have been developed by 
multiple academic and professional societies to standardize 
and recommend the available treatment options Among 
these, we can find the Osteoarthritis Research Society 
International (OARSI), American College of Rheumatology 
(ACR) and American Academy of Orthopedic Surgeons 
(AAOS)publications[39,40,41]. 
Non-pharmacological management 
The aim of the management of OA is to control the painful 
signals originated from these joints, but even more, to 
improve functionality and quality of life. Non-
pharmacological therapies should always be attempted as 
the first line of treatment for knee OA Inactivity and disuse 
are deleterious for the health of the knee joint, the absence of 
mechanical stimulation induces a more rapid cartilage 
degeneration due to cartilage softening thinning, decrease of 
glycosaminoglycan content, impaired joint mechanics and 
flexibility[42,43].Light-to-moderate physical activity 
provides multiple benefits to this patient population, besides 
the mechanical and functional improvements, they also offer 
a risk reduction of diabetes, cardiovascular events, falls, 
disability, and an improvement in mood, and self-efficacy. 
Exercise routines should be tailored to every patient’s 
needs/tolerance and preferences, high impact activities 
should be avoided, and long-term adherence should be 
maximized to increase success[44,45].There are different 
exercise modalities shown to have a favorable effect on 
patients with knee OA, routines should be performed three 
times a week, and to assess response, the patient should 
complete at least 12 sessions. 
Pharmacological management 
The vast majority of OA patients are elderly and most of 
them will have multiple comorbidities. Hence, special 
attention should be paid to the possible interactions and 
adverse effects that systemic medications can induce in this 
population. Historically, cyclooxygenase inhibitors 
(acetaminophen and NSAIDs) have been the most commonly 
used medications. But given the gastrointestinal, renal, 
cardiac, and hematological adverse effects of these 
medications, their long-term use is limited. Acetaminophen 
has shown to be inferior to NSAIDs and not superior to 
placebo for pain control, leading to some guidelines to 
abstain to recommend it as an effective medical management 
strategy for moderate-to-severe OA[45].Topical NSAIDs have 
shown to be safer, with a comparable, or slightly inferior 
efficacy than systemic NSAIDs. Onshort follow-up studies, 
they have shown to be superior to placebo in controlling pain 
during the first week of treatment but failed to prove benefit 
after 2 weeks[46].Recently, more and more awareness has 
been raised regarding the consequences of the chronic use of 
opioids. Studies also keep providing evidence that opioids 
are not superior to NSAIDs to improve OA pain or WOMAC 
scores, and the risks of their use, clearly outweigh the 
benefits[47,48].If a patient is refractory to other treatments 
and the use of an opioid is considered, Tramadol, a serotonin 
and norepinephrine reuptake inhibitor with weak μ opioid 
receptor agonist properties, has shown some benefit in the 
treatment of severe and moderate OA. This medication, 
compared to other opioids, has slightly less risk for abuse 
potential and respiratory depression[49].Duloxetine is a 
serotonin and norepinephrine reuptake inhibitor approved 
by the US Food and Drug Administration (FDA) for treatment 
of diabetic peripheral neuropathy and fibromyalgia. Recent 
studies have revealed that when used for more than 10 
weeks, this medication is better than placebo controlling 
pain and improving function in patients with OA[50]. 
Risk Factors  
Knee OA is a multi-factorial disease. The cause of OA remains 
unknown, thought there is clear evidence for major risk 
factors, such as age, obesity, joint trauma, and heavy work 
load . The risk factors can be divided into systemic (for e.g. 
age, gender, genetics, and overweight) and local 
biomechanical factors, such as joint injury and malalignment, 
overweight, and muscle weakness. Abnormal mechanical 
loading in various sport activities or during heavy work may 
activate the biochemical cascade that leads to joint 
degeneration and pain, but also even in normal mechanical 
loading if the cartilage is impaired. 
Aging is the most significant risk factor for knee OA . Knee OA 
is more common in obese subject than in subjects of normal 
weight. For example, obese women with body mass index 
(BMI) of 30- 35kg/m2 had a four times higher risk for knee 
OA than non-obese women [51]. The corresponding was 4.8 
for men. Obesity is also a major risk factor for the incidence 
of bilateral knee OA, whereas local mechanical factors are 
more often associated with unilateral OA . The effect of 
obesity on OA has been thought to be mediated through the 
increased mechanical loading of the knee and hip. This would 
lead in cartilage damage in these weight-bearing joints. 
However, obesity is also associated with hand OA, which has 
given rise to the hypothesis that both mechanical and 
metabolic factors may mediate the effects of obesity on 
joints.  
Joint injury increases the risk for knee OA. After knee injury, 
women had a three-fold and men a 5 to 6 fold risk for 
developing of knee OA, compared to healthy controls. 
Injuries to the anterior cruciate ligament associate most 
clearly with the incidence of knee OA (15-20%). As many as 
50-70% of patients with complete anterior cruciate ligament 
rupture, accompanied by concomitant injuries to the 
meniscus or other ligaments, exhibit radiographic knee OA 
changes after 15-20 years[52].. Furthermore, at 10 to 20 
years after anterior cruciate ligament or menisci injury, on 
average, half of those patients have symptomatic knee OA. 
Total meniscectomy after an isolated meniscus tear has been 
a significant risk factor for knee OA, the relative risk being 
14.0 after 21 years. Partial meniscectomy can also contribute 
to the development of knee OA.  
Heavy physical activity and occupational load are important 
risk factors for the incidence of knee OA. Heavy physical 
activity may increase the risk of especially among obese 
individuals. On the other hand, regular and moderate 
physical exercise has been shown to be associated with a 
decrease in the development of knee OA . However, most of 
the clinical or epidemiological studies have concluded that 
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jogging exercise at moderate intensity or recreational 
physical activity do not increase the risk for knee or hip OA, 
provided that the weight-bearing joints have not been 
injured. The increased risk for knee OA is also associated 
with those occupations that entail prolonged or repeated 
knee bending. The risk may be even higher in those activities 
containing both knee bending and mechanical loading .with 
respect to the other mechanical risk factors; knee 
malalignment has been reported to be associated with the 
development and progression of knee OA. Furthermore, the 
severity of malalignment can predict the decline in physical 
function Genetic factors also seem to account for the 
existence of knee OA to a degree ranging from 39-65% 
independently of the known environmental or demographic 
confounders. This suggests that the articular cartilage of 
some individuals is congenitally vulnerable to mechanical 
wear and tear. However, the prevention of OA is still a 
challenging task although there is a considerable body of 
evidence about the definite causal risk factors, such as 
obesity, joint injury and occupational load [54,55]. 
Regenerative medicine 
Aiming to stop and revert the degeneration associated with 
OA, IA injections of autologous conditioned serum (ACS), 
platelet rich plasma (PRP), and mesenchymal stem cell 
(MSC) have been tested[56,57,58].Their mechanisms of 
action is reduction of inflammatory reactions mediated by 
cytokines, and the induction of anabolism and chondrocyte 
differentiation via growth factors and stem cells contained in 
it. These methods are promising and some studies have 
reported them to be safe, well tolerated and, in some cases, 
superior to IA placebo and HA in terms of pain relief and 
knee function [56,57,58]. This is still a developing field and 
more research is required in order to define and standardize 
the optimal retrieval, storage, and preparation methods of 
these products. 
Clinical Findings  
There are several signs in knee OA that can be identified 
during the clinical inspection. These include limping due to 
joint pain, decreased walking speed as well as reduced stride 
length and frequency. Squatting may have become difficult 
for a patient suffering from knee OA. The deformity of the 
knee joint is usually a sign for advanced knee OA. Clinically 
detectable varus or valgus instability in the knee joint is 
regarded as a late sign of the disease. Coarse crepitus is 
considered to indicate the loss of congruency of the joint 
[59].  
Tenderness can be identified with palpation of the knee joint. 
Tenderness along the joint-line points to an intra-capsular 
origin for pain and point-tenderness away from the joint-line 
is indicative of a periarticular lesion. Reduced range of 
movement (ROM) easily measured with a goniometer is 
associated with physical impairment. The decreased ROM is 
mainly caused by osteophytes formation, remodeling, 
capsular thickening and can be accentuated by soft tissue 
swallowing. Muscle wasting and weakness are difficult to 
examine but can be present in knee OA. The classical signs of 
inflammation, such as heat, pain and effusion indicate 
synovitis in knee OA. Laboratory tests do not play any role in 
the diagnosis of knee OA but they can help in the differential 
diagnosis [59].  
Laboratory Findings  
A typical clinical presentation of OA does not require 
laboratory testing. The erythrocyte sedimentation rate (ESR) 
and C reactive protein (CRP) are usually normal. The full 
blood count is normal. Rheumatoid factor and antinuclear 
antibodies are usually negative. Note that these antibodies 
may be low positive and of no significance in elderly patients 
and in some chronic condition. Synovial fluid analysis usually 
indicates a low white cell count <2000ul. 
Radiological Findings  
The plain radiograph serves as the primary investigation in 
the diagnosis of knee OA, as well as in assessing the severity 
of the disease. The advantages of radiography are evident: it 
is cost-effective and relatively safe and its availability is 
excellent. However, the subjective pain and radiographic 
changes do not necessarily correlate with each other.  
Typical radiographic features in knee OA include joint space 
narrowing, osteophytes, subchondral bone sclerosis, cyst 
formation, osteochondral bodies and bone deformity. Loss of 
cartilage is an early and cardinal feature of OA leading to 
joint space narrowing in plain radiographs [60]. The 
thickness of articular cartilage varies between individuals 
and joint surfaces [60]. Therefore, no reference values for 
thickness of joint space exist. The osteophytes are a hallmark 
of OA, these being formed at joint margins by endochondral 
ossification. They can be regarded as a repair attempt and 
indicate redistribution of abnormal joint loading. Cysts are 
also typical radiographic findings in OA and occur mainly 
within the areas of bony sclerosis at sites of increased 
pressure transmission. Disintegration of the joint surface in 
OA results in the formation of osteochondral fragments. As 
these fragments are released into the joint space, they 
appear characteristically with the other established features 
of OA 
Manual Therapy  
Taping  
Taping the knee, in particular the patella is a physiotherapy 
treatment strategy recommended in the management of 
knee OA by some clinical guidelines. Knee taping involves the 
application of adhesive rigid strapping tape to the patella 
and/or associated soft tissue structures. The mechanism by 
which taping reduces pain is not clear, but my include 
changes in patellar alignment and enhanced function and 
activation of muscles.  
Electrotherapy  
Transcutaneous electrical nerve stimulation (TENS) is 
recommended in most guideline as safe adjunctive 
modalities for pain relief. Although, acupuncture may 
provide relief to some patients, there is less universal 
support for its use [61]. 
Therapeutic Exercises  
In recent years, there have been numerous studies that have 
demonstrated the effectiveness of exercise and physical 
activity for individuals with knee osteoarthritis (OA). 
Although exercise and physical activity programs have been 
found to be beneficial the overall effects of this intervention 
have been found to yield small to moderate effects at best for 
individuals with knee OA. For example a systematic review of 
the effectiveness of exercise for reducing pain and improving 
disability.  
Therapeutic exercise is a form of physical activity that is 
provided under the supervision of appropriate health 
professional for specific treatment goals. Regular physical 
activity is associated with lower mortality rates for both 
older and younger adults. Moreover, it is associated with a 
decreasing risk for a wide range of disease and conditions, 
such as cardiovascular disease, osteoporosis, falling, cancer, 
diabetes, blood pressure and osteoarthritis [62]. 
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The main reasons for prescribing exercise in general include 
(1) achieving therapeutic goals, (2) improving general health 
and reducing secondary disability, and (3) modifying 
possible risk factors in disease progression. Minor 
summarized the potential benefits of physical activity and 
exercise on OA as follows:  
1. Minimizes or slows the pathological process that takes 
place in the OA joint. Exercise increasing cartilage 
nutrition and remodeling, increases the synovial blood 
flow, decreases swelling, and improves muscle 
strength. Thus, the pathological effect of exercise may 
include slowing the cartilage degeneration process, 
decreasing bone stiffness, decreasing joint effusion and 
improving muscle strength.  
2. Decreases impairments that occur from OA by reducing 
the main impairment factors. Exercise helps in 
decreasing pain, improving strength and endurance, 
and improving range of motion and connective tissue 
elasticity.  
3. Decreases functional limitation by improving walking 
speed, gait and physical activity and decreasing 
depression and anxiety.  
Because muscle weakness plays such an important role in 
development of OA, it is increasingly evident that exercise 
plays a critical role in the management of the condition. 
Although, activity avoidance by knee osteoarthritis patients 
is common, exercise is an effective non-pharmacological 
treatment for knee OA. The American College of 
Rheumatology (ACR) has approved regular exercise as a 
therapeutic approach for the management of knee OA. 
Systematic reviews of non-pharmacological interventions 
have documented the effectiveness of exercise in reducing 
pain and disability. Evidence suggests that stretching, 
strengthening and aerobic exercise decrease pain and 
improve muscular strength, functional ability and 
psychological well-being . Exercise increases muscle 
endurance, improves proprioceptive acuity and decrease 
arthrogenic muscle inhibition of the quadriceps.  Quadriceps 
weakness is one of the most common and disabling 
impairments seen in individuals with knee osteoarthritis 
(OA). Sufficient quadriceps and hamstrings strength, both 
isometric and dynamic, is essential for undertaking basic 
activities of daily living such as standing and walking. Muscle 
strength testing has revealed that those with knee OA have a 
25% to 45% loss of knee extension strength and a 19% to 
25% loss of knee flexion strength, compared with similarly 
aged controls. There are 3 factors thought to contribute to 
knee extension and flexion weakness in those with knee OA: 
muscle atrophy, failure of voluntary muscle activity, and 
apparent weakness from increased antagonist muscle co-
contraction [63,64]. 
Strengthening  
Strengthening exercise is commonly recommended. Patients 
with knee OA tend to have reduced muscle strength as a 
consequence of reductions in physical activity and pain 
inhibition .The and have the greatest potential to generate 
and absorb forces at the knee. Many clinical studies have 
shown consistent improvements in knee extension strength 
after training, as well as reductions in pain and physical 
disability in people with knee OA.  
Strengthening the hamstring muscle has been found to 
enhance the functional ability of the deficient knee . This is 
probably due to the fact that, which an overall increase in 
both the hamstring and quadriceps strength, and increase in 
the hamstring to quadriceps ratio (H:Q), anterior-lateral 
subluxation of the tibia may be minimized .  
Stretching  
Stretching should be carried out in conjunction with 
strengthening exercises. If a specific muscle group is 
restricted, more emphasis may be placed on these areas but 
there must be stretching of all the major muscle groups of 
the lower limb, because they all have an effect on the 
biomechanics of the knee. Patients should be instructed to 
hold a stretch for 20-30 seconds for it to be effective 
.Stretching includes the quadriceps, hamstring muscles, 
iliotibial band (ITB), and Achilles tendon. Tightness of the 
ITB can affect normal patella excursion. The distal ITB fibers 
blend with the superficial and deep fibers of the lateral 
retinaculum, and tightness in the ITB can contribute to 
lateral patellar tilt and excessive pressure on the lateral 
patella. Because the ITB is a very dense and fibrous tissue, 
the effectiveness of stretching is questionable [65,66]. 
Discussion 
Osteoarthritis is a complex and multifactorial condition of 
the joints, affecting mainly the knees. Multiple hypotheses 
have been proposed but still there is not a clear etiology or 
understanding of its natural course. Based on those 
hypotheses, a wide variety of treatments have been 
developed and tested, some more successful than others, but 
ultimately all of them are aimed to decrease pain, increase 
function, and delay the necessity for a surgical joint 
replacement. All the current guidelines agree that water or 
land-based exercise should be attempted first for symptom 
control, slowly escalating towards the other therapies such 
as topical or oral medications. If they are not effective, then a 
patient can receive IA therapies, which seem to have a 
certain degree of benefit over the oral therapies with some 
contribution of the placebo effect. Among those therapies, 
one of the most studied has been IA CS, but it seems that the 
current data might not be clear given that efforts to elucidate 
the exact mechanism of action, analgesic efficacy, indication, 
and safety profile are still ongoing. Recent papers have not 
been able to provide a robust and clear answer on using IR 
CS by patients. Some authors have mentioned that the 
presence of joint effusion, synovial membrane thickness, 
high BMI, psychological factors, and knee tenderness could 
be an indicator, but there is no conclusive data on 
this[67].Perhaps white blood cells counts in the synovial 
fluid and low degree of radiographical changes on the KL 
score might be related to a better response, but it is not a 
definite answer. Part of the conflicting data is because of the 
high variability of the design of the studies that make them 
hard to be compared. Nowadays with the advancements in 
technology and ultrasound, we should aim to use this option 
whenever available to increase the rate of adequate IA 
placement of the injected substance. On October 2017, the 
FDA approved the extended-release presentation for TA 
contained in microspheres, called FX006, which theoretically, 
compared to IR CS, should provide a longer lasting pain relief 
and less adverse effects given the marked reduction on the 
serum levels of the CS. Some animal models also showed to 
be protective of the cartilage structure, and also some first 
studies have shown some adequate safety profile, but there 
are still doubts regarding its duration beyond 13 weeks. The 
truth is that this new presentation of an old medication will 
require more research to clarify some doubts regarding the 
indications and magnitude of the benefits of the IR option. 
But it seems that it might play a role if there is a concern of 
HPA axis suppression and hyperglycemia given its 
pharmacodynamics properties. The regenerative medicine 
field is developing other non- CS IA therapies, showing 
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promising results, but more knowledge and standardization 
of their therapies will be required [68]. 
Conclusion 
Despite being one of the most studied and more prevalent 
conditions of our population, knee osteoarthritis still does 
not have a clear pathophysiology or a single most efficacious 
intervention to treat the symptoms and degeneration 
associated. 
Exercises in early stages are a valuable therapy for these 
patients and it is recommended by all the medical societies. 
Other non-surgical treatments have variable efficacy and 
their success will depend on multiple variables (provider, 
equipment, patient) and their use has to be selected 
judiciously according to the specific clinical situation. 
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